# Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

> **NCT02973997** · PHASE2 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 57 (actual)

## Conditions studied

- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- Follicular Variant Thyroid Gland Papillary Carcinoma
- Metastatic Thyroid Gland Follicular Carcinoma
- Metastatic Thyroid Gland Papillary Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Follicular Carcinoma
- Recurrent Thyroid Gland Papillary Carcinoma
- Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Stage III Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Hurthle Cell Carcinoma
- Unresectable Differentiated Thyroid Gland Carcinoma
- Unresectable Thyroid Gland Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenvatinib
- **DRUG:** Lenvatinib Mesylate
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02973997
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-07
- **Primary completion:** 2022-08-15
- **Final completion:** 2023-10-08
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973997, "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02973997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*